Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$26.55 -0.2%	$29.09	$25.56 ▼ $36.45	$4.39B	0.47	2.22 million shs	1.12 million shs
FOLD Amicus Therapeutics	$6.93 -0.9%	$6.10	$5.51 ▼ $12.65	$2.15B	0.53	4.36 million shs	3.93 million shs
INVA Innoviva	$18.25 -1.0%	$19.91	$16.67 ▼ $22.00	$1.16B	0.38	788,399 shs	675,247 shs
IONS Ionis Pharmaceuticals	$40.69 -5.5%	$39.64	$23.95 ▼ $50.43	$6.86B	0.25	1.92 million shs	2.47 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.19%	-4.94%	-9.17%	-12.65%	-3.45%
FOLD Amicus Therapeutics	-0.86%	+13.05%	+14.55%	+13.98%	-30.28%
INVA Innoviva	-1.05%	-0.99%	-3.51%	-1.79%	-0.67%
IONS Ionis Pharmaceuticals	-5.48%	-6.18%	-2.61%	+24.24%	-13.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.773 of 5 stars	4.4	1.0	4.2	3.9	2.5	1.9
FOLD Amicus Therapeutics	4.1257 of 5 stars	3.4	1.0	4.3	3.6	0.0	1.9
INVA Innoviva	4.3228 of 5 stars	3.5	1.0	4.2	3.1	1.7	1.9
IONS Ionis Pharmaceuticals	4.4987 of 5 stars	4.4	3.0	3.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$41.08	54.74% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	134.09% Upside
INVA Innoviva	3.00	Buy	$40.33	121.04% Upside
IONS Ionis Pharmaceuticals	2.86	Moderate Buy	$59.38	45.94% Upside

Current Analyst Ratings Breakdown

Latest INVA, IONS, ALKS, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$60.00 ➝ $64.00
7/31/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00
7/31/2025	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $62.00
7/30/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$40.00 ➝ $42.00
7/29/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$46.00
7/21/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	2.81	$2.65 per share	10.03	$9.84 per share	2.70
FOLD Amicus Therapeutics	$528.29M	4.04	N/A	N/A	$0.66 per share	10.50
INVA Innoviva	$358.71M	3.19	$3.39 per share	5.38	$11.03 per share	1.65
IONS Ionis Pharmaceuticals	$705M	9.20	N/A	N/A	$3.96 per share	10.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.08	12.76	19.38	1.52	23.15%	24.86%	17.14%	10/23/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	16.12	N/A	-6.67%	-5.07%	-1.23%	N/A
INVA Innoviva	$23.39M	-$1.01	N/A	11.77	N/A	-16.15%	15.77%	8.41%	N/A
IONS Ionis Pharmaceuticals	-$453.90M	-$1.84	N/A	N/A	N/A	-28.25%	-45.29%	-8.99%	N/A

Latest INVA, IONS, ALKS, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	INVA Innoviva	$0.43	$0.77	+$0.34	$0.77	$87.10 million	N/A
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	$0.70	+$0.51	$0.70	$270.90 million	$452.00 million
7/29/2025	Q2 2025	ALKS Alkermes	$0.42	$0.52	+$0.10	$0.52	$343.20 million	$390.66 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.23	2.85
FOLD Amicus Therapeutics	1.92	3.21	2.29
INVA Innoviva	0.40	2.48	2.30
IONS Ionis Pharmaceuticals	0.99	2.87	2.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
FOLD Amicus Therapeutics	N/A
INVA Innoviva	99.12%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
FOLD Amicus Therapeutics	2.20%
INVA Innoviva	2.25%
IONS Ionis Pharmaceuticals	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	165.08 million	157.82 million	Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.39 million	155.25 million	Optionable

INVA, IONS, ALKS, and FOLD Headlines

Recent News About These Companies

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $408,697.20 in Stock

August 6 at 8:19 PM | marketbeat.com

Eugene Schneider Sells 9,549 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

August 6 at 5:50 AM | insidertrades.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Raiffeisen Bank International AG

August 6 at 5:07 AM | marketbeat.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires Shares of 8,059 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 6 at 4:37 AM | marketbeat.com

Jefferies Financial Group Inc. Sells 2,696,240 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

August 6 at 4:14 AM | marketbeat.com

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

August 4 at 8:46 PM | finance.yahoo.com

Brett P. Monia Sells 2,432 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

August 2, 2025 | marketbeat.com

Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells 2,432 Shares of Stock

August 2, 2025 | insidertrades.com

Ionis Pharmaceuticals (NASDAQ:IONS) Given New $64.00 Price Target at Raymond James Financial

August 1, 2025 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Given New $65.00 Price Target at HC Wainwright

August 1, 2025 | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Morgan Stanley

August 1, 2025 | marketbeat.com

Ionis (IONS) Q2 Revenue Soars 101%

August 1, 2025 | theglobeandmail.com

Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS)

August 1, 2025 | msn.com

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Strong Earnings

July 31, 2025 | marketbeat.com

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook

July 31, 2025 | zacks.com

Ionis reports second quarter 2025 financial results and highlights progress on key programs

July 31, 2025 | cadillacnews.comC

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up Following Better-Than-Expected Earnings

July 31, 2025 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

July 30, 2025 | seekingalpha.com

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

July 30, 2025 | benzinga.com

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings

July 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
By Leo Miller | July 29, 2025
View Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
Bitcoin and Dividends: A Winning Combo in These 3 ETFs
By Nathan Reiff | August 2, 2025
View Bitcoin and Dividends: A Winning Combo in These 3 ETFs
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows

INVA, IONS, ALKS, and FOLD Company Descriptions

Alkermes NASDAQ:ALKS

$26.55 -0.05 (-0.19%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$26.56 +0.00 (+0.02%)

As of 08/6/2025 07:27 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Amicus Therapeutics NASDAQ:FOLD

$6.93 -0.06 (-0.86%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$7.04 +0.11 (+1.52%)

As of 08/6/2025 07:35 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Innoviva NASDAQ:INVA

$18.25 -0.19 (-1.05%)

Closing price 08/6/2025 03:59 PM Eastern

Extended Trading

$18.36 +0.11 (+0.62%)

As of 08/6/2025 04:10 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Ionis Pharmaceuticals NASDAQ:IONS

$40.69 -2.36 (-5.48%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$40.60 -0.09 (-0.22%)

As of 08/6/2025 07:21 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time